You are here: Home: Audio Program Guide: HNCU 1 | 2008 Audio: HNCU 1 | 2008
 
 
 
To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

     
Langer, MD Corey J Langer, MD
Professor of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy
Oncology Group
Philadelphia, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Background of ECOG-E3303: Concurrent radiation therapy and cisplatin/cetuximab in unresectable, locally advanced squamous cell head and neck (H&N) cancer
Track 2 ECOG-E3303: Efficacy and toxicity
Track 3 Tradeoff of short-term side effects with amifostine for reduction of xerostomia
Track 4 Perspective on mucositis and xerostomia
Track 5 Reduced incidence of mucositis and long-term xerostomia with intensity-modulated radiation
therapy (IMRT)
audio
Track 6 Proposed randomized trial of chemoradiation therapy versus neoadjuvant docetaxel/cisplatin/
5-FU chemoradiation therapy in locally advanced H&N cancer
audio
Track 7 “Standard” evidence-based clinical treatment of H&N cancer: Concurrent chemoradiation therapy
audio
Track 8 Emerging data with cetuximab in H&N cancer
audio
Track 9 Perspective on the FLEX trial results: First-line cisplatin/vinorelbine with or without cetuximab in advanced non-small cell lung cancer (NSCLC)
audio
Track 10 Predictors of response to EGFR inhibitors in lung cancer and H&N cancer
Track 11 Frequently asked questions about the treatment of H&N cancer
Track 12 Cetuximab’s lesser-known approved indication in H&N cancer: Monotherapy in patients with platinum-refractory disease

     
Haddad, MD Robert Haddad, MD
Clinical Director/Head and Neck
Oncology Program
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
 
  Click here to download the entire interview  
Track 1 Prognosis and treatment of human papillomavirus (HPV)-related oropharyngeal cancer
Track 2 Sexual activity and the increasing incidence of HPV-related oropharyngeal cancer
Track 3 Induction cetuximab with docetaxel/cisplatin/5-fluorouracil (C-TPF) in locally advanced H&N cancer
Track 4 Clinical trials combining cetuximab with induction chemotherapy and/or radiation therapy for locally advanced H&N cancer
Track 5 Synergism between cetuximab and chemoradiation therapy
audio
Track 6 Proposed trial of induction chemotherapy evaluating C-TPF with cetuximab/carboplatin/paclitaxel
audio
Track 7 Predictors of response to EGFR monoclonal antibodies in H&N cancer
audio
Track 8 Clinical therapeutic options for patients with locally advanced H&N cancer
audio
Track 9 Cytoprotective effects of IMRT in H&N cancer
audio
Track 10 Targeted agents under investigation in H&N cancer
Track 11 Targeting VEGF, EGFR and RET with the tyrosine kinase inhibitor vandetanib
Track 12 Clinical trials of the cisplatin/docetaxel/erlotinib triplet in recurrent H&N cancer
Track 13 Delineation of a genomic profile of HPV-related oropharyngeal cancer
Track 14 Up-front versus delayed placement of percutaneous endoscopic gastrostomy (PEG) feeding tubes during radiation therapy
audio
Track 15 Role of neck dissection after chemoradiation therapy
Track 16 Use of induction chemotherapy to identify candidates for an organ-preservation approach instead of surgical resection
     
Rosenthal, MD David I Rosenthal, MD
Professor
Director, Head and Neck Translational
Research; Acting Section Chief, Head and
Neck Section, Department of Radiation
Oncology, The University of Texas
MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Current research issues in the treatment of locally advanced H&N cancer
Track 2 RTOG-0129: Conventional versus accelerated radiation therapy and concurrent cisplatin with or without resection in Stage III or IV squamous cell H&N cancer
Track 3 Evolving radiation therapy techniques in H&N cancer
Track 4 Challenges with intensity-modulated, image-guided radiation therapy in H&N cancer
Track 5 Consequences of mucositis-induced treatment interruptions and dose reductions
audio
Track 6 Development and evaluation of radioprotective agents in H&N cancer
audio
Track 7 Rationale for RTOG-0522: Concurrent accelerated, fractionated radiation therapy and cisplatin with or without cetuximab in Stage III/IV squamous cell H&N cancer
audio
Track 8 Clinical use of cetuximab with or without chemotherapy in combination with radiation therapy
audio
Track 9 Safety and tolerability of cetuximab and radiation therapy
audio
Track 10 Role of triplet induction therapy with cisplatin/fluorouracil/docetaxel in unresectable H&N cancer
Track 11 Time course of recurrences in H&N cancer
     
Vokes, MD Everett E Vokes, MD
Director, Section of Hematology/
Oncology; Vice-Chairman for Clinical
Research, Department of Medicine
Deputy Director, Cancer Research Center
John E Ultmann Professor of Medicine
and Radiation and Cellular Oncology
The University of Chicago
Chicago, Illinois
  
  Click here to download the entire interview  
Track 1 Role of chemoradiation therapy in the treatment of H&N cancer
Track 2 Approaches to reduce the long-term side effects of chemoradiation therapy for H&N cancer
Track 3 Concurrent chemoradiation therapy with or without induction chemotherapy in Stage III/IV H&N cancer
Track 4 Clinical trial strategies to incorporate cetuximab into chemoradiation therapy in Stage III/IV H&N cancer
Track 5 Selection of patients for clinical therapy incorporating cetuximab with radiation therapy or chemotherapy in H&N cancer
audio
Track 6 Therapeutic algorithm for locally advanced H&N cancer
audio
Track 7 Behavioral counseling and supportive care to ameliorate toxicity from chemoradiation therapy
audio
Track 8 Translating experience with anti-angiogenic agents in NSCLC to investigations in H&N cancer
audio
Track 9 Potential clinical implications of HPV status in H&N cancer
audio
Track 10 Frequently asked questions by medical oncologists about H&N cancer treatment